Convatec Group Plc said its treasury shares surpassed 5% of the company’s voting rights on August 6, 2026, according to a filing with the Financial Conduct Authority.
As of August 17, 2026, Convatec held 102,469,942 ordinary shares in treasury, representing 5.26% of total voting rights. The disclosure was made within four trading days of crossing the 5% threshold, in compliance with Rule 5.5.1 of the FCA’s Disclosure Guidance and Transparency Rules.
The shares were acquired through Morgan Stanley & Co. International plc as part of a buyback program announced on August 4, 2026, with a maximum size of up to $200 million. Convatec, a global medical products and technologies company, reported revenues exceeding $2 billion in 2025 and operates in approximately 90 countries with over 10,000 employees.
The company’s portfolio spans Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care, focusing on chronic condition management solutions.
